MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7.


Tyrosine kinase inhibitors (TKIs) exert potent therapeutic efficacy in non-small cell lung cancers (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutations. However, a major impediment for the effective treatment is the development of drug resistance. Some evidence supports a role for miRNAs in modulating NSCLC TKIs resistance. Here we… (More)
DOI: 10.1016/j.bbrc.2017.12.096


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics